Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(47 sites) United States
GSK Investigational Site, Los Alamitos, California GSK Investigational Site, Whittier, California GSK Investigational Site, New York, New York GSK Investigational Site, Durham, North Carolina GSK Investigational Site, Houston, Texas GSK Investigational Site, San Antonio, Texas GSK Investigational Site, Wenatchee, Washington Australia
GSK Investigational Site, Heidelberg, Victoria GSK Investigational Site, Melbourne, Victoria Belgium
GSK Investigational Site, Bonheiden GSK Investigational Site, Brussels GSK Investigational Site, Leuven GSK Investigational Site, Roeselare Brazil
GSK Investigational Site, Porto Alegre GSK Investigational Site, São Paulo GSK Investigational Site, Teresina Canada
GSK Investigational Site, Toronto, Ontario GSK Investigational Site, Sherbrooke, Quebec France
GSK Investigational Site, Paris GSK Investigational Site, Paris GSK Investigational Site, Villejuif Italy
GSK Investigational Site, Pisa Japan
GSK Investigational Site, Aichi GSK Investigational Site, Chiba GSK Investigational Site, Hokkaido GSK Investigational Site, Osaka GSK Investigational Site, Tokyo GSK Investigational Site, Tokyo Netherlands
GSK Investigational Site, Amsterdam GSK Investigational Site, Utrecht Norway
GSK Investigational Site, Lrenskog GSK Investigational Site, Oslo GSK Investigational Site, Stavanger Poland
GSK Investigational Site, Brzozów GSK Investigational Site, Warsaw South Korea
GSK Investigational Site, Seoul GSK Investigational Site, Seoul GSK Investigational Site, Seoul Spain
GSK Investigational Site, Barcelona GSK Investigational Site, Madrid GSK Investigational Site, Madrid GSK Investigational Site, Madrid GSK Investigational Site, Pamplona GSK Investigational Site, Santander GSK Investigational Site, Zaragoza Sweden
GSK Investigational Site, Lund GSK Investigational Site, Stockholm